

Applicant : Jerrold P. Weiss et al.
Serial No. : 10/715,876
Filed : November 17, 2003
Page : 2 of 8

Attorney's Docket No.: 17023.030US1 / 03067

IN THE CLAIMS

Please amend the claims as follows:

1. [Currently amended] A purified complex comprising endotoxin bound to MD-2, wherein the complex consists essentially of one molecule of endotoxin bound to one molecule of MD-2.
2. [Original] The complex of claim 1, wherein the endotoxin is a wild-type endotoxin.
3. [Original] The complex of claim 1, wherein the endotoxin is a gram-negative bacterial endotoxin.
4. [Original] The complex of claim 3, wherein the gram-negative bacterium is a *Neisseria*, *Escherichia*, *Pseudomonas*, *Haemophilus*, *Salmonella*, or *Francisella* bacterium.
5. [Original] The complex of claim 4, wherein the gram-negative bacterium is *Neisseria meningitidis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Salmonella typhimurium*, or *Francisella tularensis*.
6. [Original] The complex of claim 1 having a molecular weight of about 25,000.
7. [Cancelled] The complex of claim 1, wherein the complex consists essentially of one molecule of endotoxin bound to one molecule of MD-2.
8. [Original] The complex of claim 1, wherein the complex is soluble in water.
9. [Original] The complex of claim 1, wherein the complex binds to TLR4.
10. [Original] The complex of claim 1, wherein the complex produces TLR4-dependent activation of cells.
11. [Currently amended] ~~The complex of claim 10,~~ A purified complex comprising

Applicant : Jerrold P. Weiss et al.
Serial No. : 10/715,876
Filed : November 17, 2003
Page : 3 of 8

Attorney's Docket No.: 17023.030US1 / 03067

endotoxin bound to MD-2, wherein the complex produces TLR4-dependent activation of cells, and wherein the complex produces a half maximal TLR4-dependent activation of cells at a concentration of less than 1 nM of the complex.

12. [Currently amended] The complex of claim 11, wherein the complex produces a half maximal TLR4-dependent activation of cells at a concentration of about 30 pM or less of the complex.

13. [Currently amended] ~~The complex of claim 1~~ A purified complex comprising endotoxin bound to MD-2, wherein the endotoxin is hexa-acylated.

14. [Currently amended] ~~The complex of claim 1~~ A purified complex comprising endotoxin bound to MD-2, wherein the endotoxin is an under-acylated endotoxin.

15. [Original] The complex of claim 14, wherein the endotoxin is a tetra-acylated endotoxin.

16. [Original] The complex of claim 14, wherein the endotoxin is a penta-acylated endotoxin.

17. [Original] The complex of claim 14, wherein the complex produces less TLR4-dependent activation of cells as compared to a complex comprising an endotoxin that is hexa-acylated.

18. [Currently amended] A composition comprising a purified complex comprising endotoxin bound to MD-2 ~~the complex of claim 1~~.

19. [Currently amended] The composition of claim ~~18~~ 17, further comprising a pharmaceutically acceptable carrier.